0.00
100.00%
-228.74
After Hours:
228.95
228.95
+
Seagen Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $228.8 pivot point. If it approaches the $228.4 support level, significant changes may occur.
Previous Close:
$228.74
Open:
$0
24h Volume:
0
Market Cap:
$43.15B
Revenue:
$2.30B
Net Income/Loss:
$-750.23M
P/E Ratio:
0.00
EPS:
-4.01
Net Cash Flow:
$-701.21M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Seagen Inc Stock (SGEN) Company Profile
Name
Seagen Inc
Sector
Industry
Phone
425-527-4000
Address
21823 30th Drive SE, Bothell, WA
Seagen Inc Stock (SGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-16-23 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-16-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Feb-06-23 | Downgrade | SVB Securities | Outperform → Market Perform |
Nov-21-22 | Initiated | Truist | Hold |
Oct-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jun-29-22 | Initiated | Raymond James | Outperform |
Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
Feb-10-22 | Reiterated | BofA Securities | Buy |
Feb-10-22 | Reiterated | H.C. Wainwright | Buy |
Feb-10-22 | Reiterated | Morgan Stanley | Overweight |
Feb-10-22 | Reiterated | Needham | Buy |
Feb-10-22 | Reiterated | Piper Sandler | Neutral |
Feb-10-22 | Reiterated | RBC Capital Mkts | Sector Perform |
Feb-10-22 | Reiterated | SVB Leerink | Outperform |
Feb-10-22 | Reiterated | Wolfe Research | Peer Perform |
Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-09-21 | Initiated | Wolfe Research | Peer Perform |
Oct-15-21 | Resumed | BTIG Research | Neutral |
May-17-21 | Initiated | Evercore ISI | In-line |
Mar-31-21 | Initiated | Credit Suisse | Neutral |
Feb-01-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jan-15-21 | Upgrade | BofA Securities | Neutral → Buy |
Sep-22-20 | Reiterated | Stifel | Hold |
Aug-24-20 | Resumed | Berenberg | Buy |
Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
Jul-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
May-26-20 | Initiated | JMP Securities | Mkt Outperform |
May-01-20 | Upgrade | Guggenheim | Neutral → Buy |
May-01-20 | Reiterated | Needham | Buy |
Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-12-20 | Reiterated | H.C. Wainwright | Buy |
Feb-11-20 | Reiterated | Goldman | Buy |
Jan-28-20 | Initiated | BMO Capital Markets | Outperform |
Jan-27-20 | Initiated | BMO Capital Markets | Outperform |
Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
Dec-10-19 | Initiated | Morgan Stanley | Equal-Weight |
Dec-03-19 | Resumed | BofA/Merrill | Neutral |
Oct-22-19 | Reiterated | BofA/Merrill | Underperform |
Oct-22-19 | Reiterated | H.C. Wainwright | Buy |
Sep-27-19 | Upgrade | Goldman | Neutral → Buy |
Aug-26-19 | Initiated | BTIG Research | Neutral |
Jul-18-19 | Initiated | Deutsche Bank | Hold |
View All
Seagen Inc Stock (SGEN) Latest News
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Benzinga
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
Zacks Investment Research
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
The Motley Fool
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
Benzinga
Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune
Benzinga
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
Zacks Investment Research
Seagen Inc Stock (SGEN) Financials Data
Seagen Inc (SGEN) Revenue 2024
SGEN reported a revenue (TTM) of $2.30 billion for the quarter ending September 30, 2023, a +23.40% rise year-over-year.
Seagen Inc (SGEN) Net Income 2024
SGEN net income (TTM) was -$750.23 million for the quarter ending September 30, 2023, a -17.82% decrease year-over-year.
Seagen Inc (SGEN) Cash Flow 2024
SGEN recorded a free cash flow (TTM) of -$701.21 million for the quarter ending September 30, 2023, a +2.52% increase year-over-year.
Seagen Inc (SGEN) Earnings per Share 2024
SGEN earnings per share (TTM) was -$4.01 for the quarter ending September 30, 2023, a -16.23% decline year-over-year.
About Seagen Inc
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Cap:
|
Volume (24h):